Promoted Content
Promoted Content

Find Drugs for Infections and Infectious Diseases in Phase I Clinical Development in UNITED KINGDOM

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ChAdOx1 nCoV-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 25, 2021

            Details:

            The Phase I trial, which will enrol 30 healthy volunteers aged 18–40, will investigate the level of immune system responses generated by the ChAdOx1 nCoV-19 using this delivery technique, as well as monitoring safety and for any adverse reactions.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Foralumab,Dexamethasone

            Therapeutic Area: Infections and Infectious Diseases Product Name: NI-0401

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 04, 2021

            Details:

            The scientific approaches underlying this clinical study could potentially be effective against SARs, MERS, and all variants of coronaviruses. Anecdotal feedback from Foralumab-treated patients was positive and suggests that the treatment was well-tolerated.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVI-VAC

            Therapeutic Area: Infections and Infectious Diseases Product Name: COVI-VAC

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Codagenix

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 14, 2020

            Details:

            The study will assess the safety and immunogenicity of a single-dose nasal vaccine candidate COVI-VAC in 48 healthy young adult volunteers.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Foralumab,Dexamethasone

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 02, 2020

            Details:

            Trial arranged in collaboration with Harvard Medical School and Dr. Howard Weiner. A patent application was filed in July 2020 to protect the potential use of nasally administered Foralumab to treat COVID-19 either alone or in combination with other anti-viral drugs.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AZD7442

            Therapeutic Area: Infections and Infectious Diseases Product Name: AZD7442

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: BARDA

            Deal Size: $486.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement October 09, 2020

            Details:

            AstraZeneca plans to supply up to 100,000 doses of AZD7442 starting towards the end of 2020 and the US Government can acquire up to an additional one million doses in 2021 under a separate agreement.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AZD7442

            Therapeutic Area: Infections and Infectious Diseases Product Name: AZD7442

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 25, 2020

            Details:

            Notable abstracts include data from the first randomized controlled Phase 3 study of a PCSK9 inhibitor, Repatha, in pediatric patients with heterozygous familial hypercholesterolemia (HeFH), which will be presented as a late-breaking abstract in an oral presentation.